-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Pegargiminase in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Pegargiminase (ADI-PEG 20) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pemigatinib in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pemigatinib in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Pemigatinib (Pemazyre) is acts as an anti...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selinexor in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Selinexor in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Selinexor (Xpovio, Nexpovio) is an antineoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ibudilast in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ibudilast in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Ibudilast (Ketas) is an anti-inflammatory and neuroprotective...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Relatlimab in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Relatlimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Relatlimab (BMS-986016) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Cemiplimab (Libtayo) is an anti-neoplastic agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: AZD-1390 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-207 in Recurrent Medulloblastoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Recurrent Medulloblastoma Drug Details: G-207 is under development for medulloblastoma, primitive neuroectodermal tumor,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – WP-1066 in Recurrent Medulloblastoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.WP-1066 in Recurrent MedulloblastomaDrug Details:WP-1066 is under development for the treatment of metastatic melanoma, glioblastoma, head...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Apatinib Mesylate in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Apatinib Mesylate (Aitan) is an anti-neoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6156 in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.RG-6156 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: RG-6156 is under development for the treatment of glioblastoma multiforme...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-157 in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. APG-157 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: APG-157Â is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EO-2401 in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EO-2401 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: EO-2401 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Retifanlimab in Recurrent Glioblastoma Multiforme (GBM)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Retifanlimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Retifanlimab (Zynyz) is a humanized IgG4...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Photobac in Recurrent Glioblastoma Multiforme (GBM)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Photobac in Recurrent Glioblastoma Multiforme (GBM)Drug Details:Photobac is under development for the treatment of recurrent glioblastoma...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DSP-0390 in Recurrent Malignant Glioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.DSP-0390 in Recurrent Malignant GliomaDrug Details:DSP-0390 is under development for the treatment of solid tumor, brain...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Recurrent Glioblastoma Multiforme (GBM)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Regorafenib (BAY 73-4506, Stivarga) is an...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Epacadostat in Recurrent Glioblastoma Multiforme (GBM)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Epacadostat in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Epacadostat (INCB-24360) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Atezolizumab (Tecentriq) is an antineoplastic agent. It...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.